Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Trobisch, A; Marterer, R; Gorkiewicz, G; Flaschberger, S; Lackner, H; Seidel, M; Sperl, D; Karastaneva, A; Kohlmaier, B; Egger, M; Urban, C; Benesch, M; Strenger, V.
Invasive mucormycosis during treatment for acute lymphoblastic leukaemia-successful management of two life-threatening diseases.
Support Care Cancer. 2020; 28(5):2157-2161
Doi: 10.1007/s00520-019-04962-3
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Strenger Volker
- Trobisch Andreas
- Co-Autor*innen der Med Uni Graz
- Benesch Martin
- Egger Markus
- Gorkiewicz Gregor
- Karastaneva Anna
- Kohlmaier Benno
- Lackner Herwig
- Marterer Robert
- Seidel Markus
- Sperl Daniela Ingrid
- Urban Ernst-Christian
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- A 5-year-old patient treated for acute lymphoblastic leukaemia (ALL) developed proven pulmonary invasive fungal disease (IFD) due to Actinomucor elegans. While completing ALL treatment according to AIEOP ALL protocol 2009 for further 15 months, antifungal treatment with liposomal amphotericin B and intermittent additional posaconazole was continued until immune reconstitution 7 months after the end of ALL treatment. Repeated imaging guided treatment decisions. Twenty-six and 19 months after the end of ALL treatment and antifungal treatment, respectively, the patient is still in the first complete remission and shows no signs of active invasive fungal disease (IFD).
- Find related publications in this database (Keywords)
- ALL
- Mucormycosis
- IFD
- Antimycotic treatment
- Chemotherapy